लोड हो रहा है...
Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
Breast cancer is the most common cancer in a woman with a five-year survival of patients with metastatic disease is estimated at 23%. Ado-trastuzumab emtansine (T-DM1) is a HER2-antibody drug conjugate currently approved for the treatment of HER2-positive pre-treated metastatic breast cancer (BC). W...
में बचाया:
| में प्रकाशित: | Cureus |
|---|---|
| मुख्य लेखकों: | , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Cureus
2019
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6886650/ https://ncbi.nlm.nih.gov/pubmed/31824803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6036 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|